Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLZ-2002 in Charcot-Marie-Tooth Type 1
NCT05947578Phase 1Completed
- Sponsor
- Cellatoz Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLZ-2002 in Charcot-Marie-Tooth disease type 1 (CMT1), sponsored by Cellatoz Therapeutics, Inc. Primary endpoint: Safety and tolerability of intramuscular injections of CLZ-2002 at 24 weeks. Started Jun 2023; status: completed.
02
Drugs
CLZ-2002
03
Conditions
Charcot-Marie-Tooth disease type 1 (CMT1)
Beyond the preview
Go deeper on NCT05947578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947578.